Cargando…
Erratum to: Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay
Autores principales: | Heywood, Wendy E., Galimberti, Daniela, Bliss, Emily, Sirka, Ernestas, Paterson, Ross W., Magdalinou, Nadia K., Carecchio, Miryam, Reid, Emma, Heslegrave, Amanda, Fenoglio, Chiara, Scarpini, Elio, Schott, Jonathan M., Fox, Nick C., Hardy, John, Bhatia, Kailash P., Heales, Simon, Sebire, Neil J., Zetterberg, Henrik, Mills, Kevin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4763435/ https://www.ncbi.nlm.nih.gov/pubmed/26907468 http://dx.doi.org/10.1186/s13024-016-0086-3 |
Ejemplares similares
-
Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay
por: Heywood, Wendy E., et al.
Publicado: (2015) -
CSF pro-orexin and amyloid-β38 expression in Alzheimer's disease and frontotemporal dementia
por: Heywood, Wendy E., et al.
Publicado: (2018) -
A targeted proteomic multiplex CSF assay identifies increased malate dehydrogenase and other neurodegenerative biomarkers in individuals with Alzheimer's disease pathology
por: Paterson, R W, et al.
Publicado: (2016) -
Role of Oxidative Damage in Alzheimer’s Disease and Neurodegeneration: From Pathogenic Mechanisms to Biomarker Discovery
por: Buccellato, Francesca Romana, et al.
Publicado: (2021) -
Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer’s disease
por: Heslegrave, Amanda, et al.
Publicado: (2016)